Ok last of this series of posts of interesting snippets from the recent Merck R&D day. See below for commentary and slides regarding their unique monoclonal antibody program for C. difficile associated diarrhea (CDAD). Important for those who follow Optimer OPTR and Cubist CBST, among others. I am working on a more complete analysis of the prospects for this MK3415A program, which is currently in phase 3 development.
Your support is greatly appreciated